Rubric condition met: Small RCTs only in clinical/older populations (adults over 70 with fatigue; hepatic encephalopathy) extrapolated to healthy adults
Controlled trials in adults over 70 with fatigue (96 participants; the abstract does not describe the comparison group) and in hepatic encephalopathy (121 patients) reported lower mental-fatigue scores, but every fatigue trial found shares the same research team (Malaguarnera M is an author on each). The only fatigue data in the 2019 Cochrane review of that team's hepatic encephalopathy trials come from the same 121-patient trial [11], re-analyzed; the review rated it very low quality and judged the effects uncertain. No trials in healthy adults were found. Both positive trials come from one team at high risk of bias, and the outcomes are self-reported, so direction is none (limited, mixed), not benefit.
How sure are we?
Evidence maturity: Emerging Every supporting fatigue trial comes from one research group, so the replication rule holds it at Emerging.
Tested as: Acetyl-L-carnitine
Who paid for the studies
Not stated (treated as not independent)
Risk of bias
High. Cochrane rated the group's trials high risk of bias, underpowered and very low quality.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
1.5 g a day or more
Rules applied
B1: risk of bias (logged, no further change): Over half the supporting studies are high risk of bias; step stops at C; B2: one funder or group (logged, no further change): Every supporting trial shares one research group
Could rise: Would move to C benefit with an independent, preregistered RCT of at least 100 adults positive on a fatigue primary outcome; to B with two such trials.
Could fall: Stays at C none unless two adequately sized independent RCTs are null, which would support N.
Science is provisional. This grade reflects the evidence we found as of . Next review: .
Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.
Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.Show the numbers
Study
Year
Design
Participants
Result
Malaguarnera 2008
2008
RCT
96
result not recorded
Malaguarnera 2011
2011
RCT
121
result not recorded
Mart 2019
2019
meta-analysis
398
result not recorded
Malaguarnera 2022
2022
RCT
92
result not recorded
Acetyl-L-carnitine for patients with hepatic encephalopathy.
Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I. Acetyl-L-carnitine for patients with hepatic encephalopathy Cochrane Database Syst Rev, 2019. PMID 30610762
Result not recorded
Design
Cochrane systematic review and meta-analysis of 5 RCTs
Sample
n = 398
Population
Adults with cirrhosis and hepatic encephalopathy (clinical population)
Funding
not stated
Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
Malaguarnera M, Vacante M, Giordano M. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study Am J Clin Nutr, 2011. PMID 21310833
Result not recorded
Design
Randomized double-blind placebo-controlled trial, 90 days
Sample
n = 121
Population
Adults with cirrhosis and overt hepatic encephalopathy (clinical population)
Funding
not stated
Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.
Malaguarnera G, Catania VE, Bertino G. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial Curr Pharm Des, 2022. PMID 36043711
Result not recorded
Design
Randomized double-blind placebo-controlled trial (abstract also calls it 'observational')
Sample
n = 92
Population
Prefrail older adults (older population)
Funding
not stated
Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
Malaguarnera M, Gargante MP, Cristaldi E. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue Arch Gerontol Geriatr, 2008. PMID 17658628
Result not recorded
Design
Randomized placebo-controlled trial
Sample
n = 96
Population
Adults over 70 with chronic fatigue complaints meeting fatigue-syndrome criteria (clinical/older population)
Funding
not stated
Search and history
Search (): (acetylcarnitine[ti] OR acetyl-L-carnitine[ti] OR "acetyl L carnitine"[ti]) AND (fatigue[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])
Graded C (awaiting approval)
C to C (awaiting approval)
C to C (awaiting approval) (maturity: emerging): Maturity, bias summary and re-check date added
C to C (approved) (maturity: emerging): Editor sign-off November 16, 2026: grade matches the editor-approved final page
A, strong: what grade A means
At least one meta-analysis or three independent randomized trials in the relevant healthy population, pointing the same way, with low or some risk of bias, at doses legally available.